HANNOVER, Germany, December 9 /PRNewswire/ -- The German biotech company BioVisioN AG today announced the closing of a service agreement with the Swiss pharmaceutical company Novartis Pharma AG. The agreement comprises the evaluation of clinical samples provided by Novartis using BioVisioN's proprietary Differential Peptide Display(R) technology. The aim is to find and identify clinically relevant peptides (small proteins). BioVisioN values the agreement as a further evidence for the capability and the increasing acceptance of their Peptidomics(R )-Technologies.
BioVisioN's Chief Business Officer Dr. Rainer Voegeli: "Thanks to our consequent development strategy we were able to establish highly sensitive and well reproducible technologies for the identification of peptide biomarkers and other pharmaceutically relevant peptides in the context of clinical studies and preclinical research that offer significant advantages compared to other existing approaches." BioVisioN AG specialises in the identification of disease-relevant peptides and proteins using Peptidomics(R) in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to ist technology also in fee-for-service contracts as a Biological Research Organisation.
Dr. Rainer Voegeli, Head of Business Development
CONTACT: Pressekontakt: Dr. Rainer Voegeli, Head of BusinessDevelopment, BioVisioN AG, Feodor-Lynen-Str. 5, 30625 Hannover,Fon: +49(0)511-538-896-0, Fax: +49(0)511-538-896-66,firstname.lastname@example.org://www.peptidomics.com/